



COMPANY NEWSLETTER

January 2019

MESSAGE FROM THE MANAGING DIRECTOR



Hello and welcome to our first newsletter for 2019, which is poised to be another exciting year for Proteomics International. The rollout of our world leading predictive diagnostic test for diabetic kidney disease, PromarkerD, remains at the forefront of our activities, and following closely behind are advancing the development of new biomarkers for major diseases, and growing demand for our analytical services.

We've been excited to announce that Proteomics International signed a collaborative agreement with Janssen Research & Development, LLC, the research arm of Johnson & Johnson. This partnership will see PromarkerD predictive technology used to propel drug discovery for diabetic kidney disease.

Production of the PromarkerD kit version has been completed. This uses a standard immunoassay format and now sits alongside the existing Laboratory Developed Test mass spectrometry version to offer a comprehensive choice of technology platforms for delivering PromarkerD. In combination they will accelerate PromarkerD rollout in the months ahead.

As part of the continued drive to license PromarkerD into new jurisdictions I will be joining our Director Roger Moore on a trade visit to Japan at the beginning of February. The Proteomics International team will also be attending the 24th Annual Lorne Proteomics Symposium. Please contact us if you would like to organise a meeting in either location.

This edition of the newsletter also includes a feature on precision medicine and Complementary Diagnostics (CDx), a key route of application for PromarkerD, and an area that is now reaching into all aspects of medical treatment.

Richard Lipscombe, PhD
Managing Director

IN THIS ISSUE

- ❑ **Collaboration agreement signed with US big pharma**
- ❑ **Precision medicine and Complementary Diagnostics (CDx)**
- ❑ **PromarkerD kit version completed**
- ❑ **PromarkerD test enters Europe**
- ❑ ***Recent events:* Diabetes Technology Meeting
AusBiotech 2018**
- ❑ ***Upcoming events:* Japan Trade Visit
Lorne Proteomics**
- ❑ **Adelaide Equity Partners and Scintilla Capital appointed as Corporate Advisors**


Collaboration agreement signed with US big pharma

Proteomics International signed a collaborative agreement with Janssen Research & Development, LLC. The study will see PromarkerD predictive technology used to accelerate drug discovery for diabetic kidney disease. The collaboration will also evaluate how PromarkerD performs in predicting heart disease, another major complication caused by diabetes and a new application for PromarkerD.

The collaboration has the potential to establish PromarkerD as a Complementary Diagnostic (CDx) test for the therapeutic treatment of diabetes complications. [\[Full article\]](#)

Diagnostic tests can be essential for the safe and effective use of therapeutics (*companion diagnostic*), or may help weigh up the risks and benefits of a treatment without restricting drug access (*complementary diagnostic*).

For example if you are a diabetic



PromarkerD can tell you if you will get Kidney Disease in the next 4 years

PromarkerD can be used as a complementary diagnostic for drugs to treat diabetic kidney disease.

Precision medicine and Complementary Diagnostics (CDx)

Our genes, environment and lifestyle can all influence how susceptible we are to a disease, and how we will respond to a particular treatment. But until now, it has been almost impossible to target treatments to a specific individual. Medicine has been largely aimed at the average.

Enter precision medicine. Sometimes called personalised medicine, precision medicine is an emerging approach that takes individual variability into account in the treatment or prevention of disease. It combines knowledge of a person's unique protein and biochemical make up to allow prevention and treatment strategies to be tailored to their individual needs.

Precision medicine often employs diagnostic testing to examine the proteins or genes in a patient's blood. These tests can provide crucial information such as how a patient might respond to a specific treatment, how likely they are to experience side effects and how quickly a disease is progressing.

When a diagnostic test is used alongside a drug therapy, it is known as a companion or complementary diagnostic (CDx).

To date, much of the attention on precision medicine has focused on well-supported clinical areas such as cancer and 'rare' single-gene disorders that cause disability in children. But a 2018 report commissioned by Australia's Chief Scientist—The future of precision medicine in Australia—says the opportunities to improve health outcomes for complex disorders such as diabetes and cardiovascular disease are equally exciting.



PromarkerD kit version completed for commercial release

Manufacture of the PromarkerD immunoassay kit was completed following production of the key antibody reagents in Puerto Rico, and manufacture of the kit in certified facilities in California (in partnership with licence partner Omics Global Solutions).

[\[Full article\]](#)



PromarkerD test enters Europe

Proteomics International announced a licence deal that will see the PromarkerD test enter the Spanish market with Patia Europe. Currently there are 3.6 million adults with diabetes in Spain, where, like the rest of Europe, the incidence of diabetes is increasing rapidly. The licence permits Patia Europe to commercialise the PromarkerD mass spectrometry "Laboratory Developed Test" (LDT), which permits fast adoption of a new test in advanced markets.

[\[Full article\]](#)

Recent events:

18th Annual Diabetes Technology Meeting

November 9, 2018

Results verifying the performance of the new PromarkerD immunoassay were presented at the 18th Annual Diabetes Technology Meeting in North Bethesda, Maryland, USA.

AusBiotech

October 31-November 2, 2018

Proteomics International exhibited at AusBiotech at the Brisbane Convention and Exhibition Centre from October 31 to November 2, 2018. The company was part of the Team Perth Pavilion.

Upcoming events:

Japan Trade Visit

February 3-7, 2019

Managing Director Dr Richard Lipscombe and Director Roger Moore will visit Japan for commercialisation discussions as part of the continued drive to license PromarkerD in new jurisdictions.

24th Annual Lorne Proteomics Symposium

February 7-11, 2019

The Proteomics International team will be at the 24th Annual Lorne Proteomics Symposium in Victoria. Find us at Booth #11.

Proteomics appoints Adelaide Equity Partners and Scintilla Capital as Corporate Advisors

Proteomics International has appointed new advisors to help unlock investor value and establish the foundation for further corporate growth. Adelaide Equity is an independent investment bank, specialising in the provision of corporate advisory services for small-mid ASX listed companies in the healthcare, natural resource, industrial and technology sectors. Scintilla Capital is a specialist fund manager focused on high growth microcap ASX listed companies that target the disruptive technologies of tomorrow.

[\[Full article\]](#)

PROTEOMICS – FAST FACT PANEL

COMPANY CONTACTS

Dr Richard Lipscombe
Managing Director

Mr Chuck Morrison
Head of Business Development

Mr Shane Herbert
Customers Services Manager

Dr Pearl Tan
Chief Operating Officer

Dr Scott Bringans
Research Manager

Susan Fitzpatrick-Napier
Media Contact

AGENTS

India

Proteomics International – India
www.proteomicsindia.com
info-india@proteomics.com.au
P: + 91 8527 699 192

Malaysia/ Indonesia/ Thailand

Apical Scientific Sdn. Bhd.
www.apicalscientific.com
info@apicalscientific.com
P: + 603 8943 3252

Singapore

Axil Scientific Pte Ltd
www.axilscientific.com
peptide@axilscientific.com
P: + 65 6775 7318

Japan

Leave a Nest Co. Ltd
www.leaveanest.com
info@leaveanest.com
P: + 81 3 6277 8041

Hong Kong/ China

Asia Bio Channel Limited
www.asiabiochannel.com
bcoissac@asiabiochannel.com
P: + 852 9845 4791

Latin America

LinkPharma LLC
www.linkpharma.co
customerservice@linkpharmaus.com
P: +1 813 319 3972

Listing

Australian Securities Exchange

Stock Code

ASX: PIQ

Investor Relations

Dirk van Dissel (Adelaide Equity Partners)
dvandissel@adelaideequity.com.au
P: +61 8 8232 8800

Cash Position

A\$2.93 million (31/12/2018)

Issued Capital – Ordinary shares

80.4 million

Market Capitalisation based on share price of 35 cents

A\$26.5 million

Proteomics International is a wholly owned subsidiary of Proteomics International Laboratories Limited (ASX: PIQ)

FOR FURTHER INFORMATION PLEASE CONTACT:

Proteomics International Laboratories Limited

 +61 8 9389 1992

 info@proteomics.com.au (general)
bd@proteomics.com.au (business development)

 www.proteomics.com.au
www.proteomicsinternational.com

 QEII Medical Centre
6 Verdun Street, Nedlands
Perth WA 6009 Australia

Forward looking statement

Any forward looking statements in this newsletter have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors many of which are outside Proteomics International Laboratories Limited's control. Important factors that could cause actual results to differ materially from any assumptions or expectations expressed or implied in this newsletter include known and unknown risks. As actual results may differ materially to any assumptions made in this newsletter, you are urged to view any forward looking statements contained in this newsletter with caution. This newsletter should not be relied on as a recommendation or forecast by Proteomics International Laboratories Limited, and should not be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.